Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
Korea’s BioLeaders To Invest $10 Million in Israel’s Weizmann Institute Anti-Cancer Therapy
Error: Contact form not found.
by Adi Pick / CTech
The Weizmann Institute of Science in Rehovot, Israel. Photo: Avi Deror via Wikimedia Commons.
CTech – Yongin, South Korea-headquartered biomedical company Bioleaders is looking to Israeli research institute the Weizmann Institute of Science for anti-cancer technology. BioLeaders has agreed to commit $10 million towards a company being spun off of Yeda Research and Development, Weizmann’s technology transfer arm, the institute announced Tuesday.
The spinoff, which will be jointly held by Yeda and BioLeaders, will develop a drug based on research from the institute’s molecular cell biology department.
The company expects to establish operations and recruit staff to its headquarters in the Kiryat Weizmann Science Park in Ness Ziona, near the Weizmann Institute of Science, Weizmann said.
Founded in 2000, BioLeaders is listed on the Korea Exchange and reported revenues of KRW 7.6 billion ($6.7 million) in 2017. This is BioLeader’s first investment in Israel.
